Clinical trials
Primary Central Nervous System Lymphoma clinical trials
Below are recruiting primary central nervous system lymphoma clinical trials, each written for real people, not researchers. We’re tracking 93 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06208735RecruitingPhase 1
CLIC-2201 for relapsed or refractory B-cell cancers
This early-phase trial tests a new treatment called CLIC-2201 for people whose B-cell lymphoma or leukemia has not responded to other treatments or has come back. It aims to see if this therapy can help when other options have failed.
Calgary, AlbertaAges 1 year+ - NCT06464861RecruitingPhase 1
Sequential CD19 CAR-NK and CAR-T for B-cell lymphoma
This trial tests a new combination treatment: first, natural killer cells (NK cells) that are engineered to find CD19, followed by CAR-T cells (also targeting CD19). It is for people with B-cell lymphoma that has come back or not responded to standard treatments.
Hangzhou, ZhejiangAges 18–75 - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Scottsdale, ArizonaAges 18 years+ - NCT04836507RecruitingPhase 1/Phase 2
Study of a lab-made cell therapy for lymphoma and leukemia
This Phase 1/2 trial tests CRC01, a lab-made immune cell therapy, for adults whose lymphoma or B-cell leukemia has come back or did not respond to treatment. If you qualify, the study aims to see how safe CRC01 is and whether it can shrink tumors and improve outcomes.
SeoulAges 19 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT05998642RecruitingPhase 2
Ibrutinib combo for newly diagnosed brain lymphoma
This trial tests a combination of ibrutinib, methotrexate, and rituximab for people with newly diagnosed primary CNS lymphoma who cannot have a stem cell transplant. It aims to see if this drug combination can effectively treat the disease.
Calgary, AlbertaAges 18 years+ - NCT06486051RecruitingPhase 2
CAR T-cell therapy for adults with relapsed large B-cell lymphoma
This trial tests a new treatment called atlacabtagene autoleucel, which uses your own immune cells to fight the lymphoma. It's designed for people whose lymphoma has come back or not responded to initial treatments.
Auckland, AucklandAges 18–75 - NCT06271057RecruitingPhase 2
Golcadomide after CAR T-cell for high-risk large B-cell lymphoma
This trial tests a new drug, golcadomide, given after CAR T-cell therapy to prevent relapse in people with aggressive large B-cell lymphoma who are at high risk. If you've had or are about to receive CAR T-cells, this study may help keep your lymphoma in remission.
CréteilAges 18 years+ - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT06973811RecruitingPhase 2
ZR-MTX for Newly Diagnosed Eye Lymphoma
This trial tests a combination of two drugs, zanubrutinib and methotrexate, for people with a newly diagnosed lymphoma that affects only the eyes. The goal is to see if this treatment works well and is safe.
Beijing, Beijing MunicipalityAges 18–75 - NCT06737250RecruitingPhase 2
Testing a new drug combo for relapsed brain lymphoma
This trial tests a combination of three drugs (poseltinib, rituximab, and lenalidomide) for people with primary central nervous system lymphoma that has come back or not responded to earlier treatment. The goal is to see if this new mix can help control the disease.
BusanAges 19–80 - NCT04627753RecruitingPhase 2
Lenalidomide plus rituximab to prevent brain lymphoma return
This trial studies whether lenalidomide and rituximab can help keep primary CNS lymphoma from coming back after initial chemotherapy. It may be an option if you cannot do a transplant and you can take pills.
SeoulAges 19 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT03017820RecruitingPhase 1
Vaccine plus immune drugs for relapsed blood cancers
This early-phase trial tests a personalized-style vaccine (called VSV-hIFNβ-NIS) given alone or with other cancer-fighting medicines, including drugs that help the immune system attack. It is designed for people with certain relapsed or hard-to-treat multiple myeloma, acute myeloid leukemia, or lymphomas, to see if the treatment can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT07022223RecruitingPhase 2
Orelabrutinib plus rituximab for first treatment of marginal zone lymphoma
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
Hangzhou, ZhejiangAges 18 years+ - NCT04848064RecruitingPhase 1
Natural killer cells plus mogamulizumab for skin lymphoma
This early-phase study tests a combination of “natural killer” immune cells and a medicine called mogamulizumab to treat certain skin lymphomas that have come back or did not respond. It may help your immune system better find and attack cancer cells.
Columbus, OhioAges 18 years+ - NCT07356245RecruitingPhase 2
Ruxolitinib after stem cell transplant for T-cell lymphoma
This trial tests whether taking ruxolitinib after a stem cell transplant can help prevent T-cell lymphoma from coming back. It is for patients whose lymphoma is in remission (partial or complete) after their transplant.
Columbus, OhioAges 18 years+ - NCT06911502RecruitingPhase 3
Golcadomide plus rituximab for relapsed follicular lymphoma
This trial tests a new drug, Golcadomide, combined with rituximab, for people with follicular lymphoma that has come back or hasn't responded to prior treatment. The goal is to see if this combination works better than other treatments your doctor might choose.
Birmingham, AlabamaAges 18 years+ - NCT06742502RecruitingPhase 2
Immunotherapy plus R-CHOP for untreated PMBCL
This trial is testing a new combination of immunotherapy (sintilimab and rituximab) followed by standard chemotherapy (R-CHOP) for people with untreated primary mediastinal B-cell lymphoma (PMBCL). It aims to see if this approach can improve outcomes for this specific type of lymphoma.
Fuzhou, FujianAges 18–75 - NCT02579967RecruitingPhase 2
Stem cell transplant for primary immune system disorders
This study tests whether an allogeneic stem cell (bone marrow) transplant can correct an inherited immune problem in people with severe primary immunodeficiencies. It may help reduce life-threatening infections and improve quality of life, depending on your overall health and donor match.
Bethesda, MarylandAges 4–75 - NCT06050694RecruitingPhase 2
Testing glofitamab plus chemo for untreated DLBCL
This trial tests a new drug called glofitamab combined with standard Pola-R-CHP chemotherapy for people with untreated DLBCL. The goal is to see if using PET scans and blood tests early on can guide treatment and improve outcomes.
Toronto, OntarioAges 18 years+
Hear when a new Primary Central Nervous System Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for primary central nervous system lymphoma?
- Yes. Clin2 currently lists 93 recruiting primary central nervous system lymphoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a primary central nervous system lymphoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a primary central nervous system lymphoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.